Association of endothelial nitric oxide synthase glu298asp gene polymorphism with the risk of end-stage renal disease

Renal Failure

Volumn 35, Issue 4, 2013, Pages 573-578

  Zhou, Tian Biao ^a   Yin, Sheng Sheng ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

End stage renal disease; Endothelial nitric oxide synthase; ENOS; Gene polymorphism; Glu298Asp; Meta analysis

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE;

AFRICAN AMERICAN; ALLELE; ASIAN; BRAZIL; CAUCASIAN; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KIDNEY FAILURE; META ANALYSIS; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS;

ENDOTHELIAL CELLS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY FAILURE, CHRONIC; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84876392737     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.773834     Document Type: Review

References (26)

1. Sowjanya B, Sreenivasulu U, Naidu JN, et al. End stage renal disease, differential diagnosis, a rare genetic disorder: Bardetbiedl syndrome: Case report and review. Indian J Clin Biochem. 2011;26:214-216
2. Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: A systematic literature review. BMC Nephrol. 2011;12:35
3. Kuo CC, Lee CT, Ho SC, et al. Hemodialysis and the risk of stroke: A population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Nephrology (Carlton). ;17:243-248
4. Fassett RG, Robertson IK, Mace R, et al. Palliative care in endstage kidney disease. Nephrology (Carlton). 2011;16:4-12
5. Zheng K, Newman MW, Veinot TC, et al. Using online peermentoring to empower young adults with end-stage renal disease: A feasibility study. AMIA Annu Symp Proc. 2010;2010: 942-946
6. McDonald SP, Tong B. Morbidity burden of end-stage kidney disease in Australia: Hospital separation rates among people receiving kidney replacement therapy. Nephrology (Carlton); 16:758-766
7. Trabulus S, Guven GS, Altiparmak MR, et al. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease. Mol Biol Rep. 2012;39:6995-7001
8. Prakash S, Prasad N, Sharma RK, et al. Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease. Cytokine. 2012;58:261-266
9. George GP, Mittal RD. Genetic polymorphisms in MHCencoded antigen processing gene TAP2: A case-control study in end-stage renal disease patients of North India. Transpl Immunol. 2011;24:220-223
10. Borkar M, Tripathi G, Sharma RK, et al. Chemokine (CCR) and fractalkine (CX3CR) receptors and end stage renal disease. Inflamm Res. 2011;60:399-407
11. Larsen T, Mose FH, Bech JN, et al. Effect of nitric oxide inhibition on blood pressure and renal sodium handling: A doseresponse study in healthy man. Clin Exp Hypertens. 2012;34:567-574
12. Schwartz IF, Grupper A, Soetendorp H, et al. Attenuated glomerular arginine transport prevents hyperfiltration and induces HIF-1alpha in the pregnant uremic rat. Am J Physiol Renal Physiol. 2012;303:F396-404
13. Tsai KD, Chang WW, Lin CC, et al. Differential effects of LY294002 and wortmannin on inducible nitric oxide synthase expression in glomerular mesangial cells. Int Immunopharmacol. 2012;12:471-480
14. Zhou TB, Qin YH, Su LN, et al. ACE I/D gene polymorphism can't predict the steroid responsiveness in Asian children with idiopathic nephrotic syndrome: A meta-analysis. PLoS One. 2011;6:e19599
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101
16. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634
17. de Prado A, Donate T, Martinez E, et al. Endothelial nitric oxide synthase gene polymorphism in dialysis patients. Adv Perit Dial. 2002;18:18-20
18. Nagase S, Suzuki H, Wang Y, et al. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem. 2003;244:113-118
19. Thaha M, Pranawa, Yogiantoro M, et al. Association of endothelial nitric oxide synthase Glu298Asp polymorphism with end-stage renal disease. Clin Nephrol. 2008;70:144-154
20. Marson BP, Dickel S, Ishizawa MH, et al. Endothelial nitric oxide genotypes and haplotypes are not associated with endstage renal disease. DNA Cell Biol. 2011;30:55-59
21. El-Din BS, Hamdy SM. Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients. Ren Fail. 2011;33:878-884
22. Noiri E, Satoh H, Taguchi J, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension. 2002;40:535-540
23. Casas JP, Bautista LE, Humphries SE, et al. Endothelial nitric oxide synthase genotype and ischemic heart disease: Metaanalysis of 26 studies involving 23028 subjects. Circulation. 2004;109:1359-1365
24. Yu CK, Casas JP, Savvidou MD, et al. Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and development of pre-eclampsia: A case-control study and a meta-analysis. BMC Pregnancy Childbirth. 2006;6:7
25. Su MT, Lin SH, Chen YC. Genetic association studies of angiogenesis- and vasoconstriction-related genes in women with recurrent pregnancy loss: A systematic review and meta-analysis. Hum Reprod Update. 2011;17:803-812
26. Shaik AP, Sultana A, Bammidi VK, et al. A meta-analysis of eNOS and ACE gene polymorphisms and risk of pre-eclampsia in women. J Obstet Gynaecol. 2011;31:603-607